Exploring IL_18 Levels in Alzheimer’s disease progression Using ELISA Methodology

Alzheimer's disease (AD) is marked by cognitive decline and involves complex pathophysiology, including neuroinflammation. Interleukin-18 (IL-18), a proinflammatory cytokine, is linked to AD's progression, with elevated levels found in patients. IL-18's role in neuroinflammation, including its production by microglia and effects on other immune cells, contributes to AD's pathology. This study explores the role of Interleukin-18 (IL-18) levels in the progression of Alzheimer's Disease (AD) using the Enzyme-Linked Immunosorbent Assay (ELISA) methodology. It investigates the complex pathophysiology of AD, highlighting the significance of neuroinflammation and the contribution of IL-18 as a proinflammatory cytokine in the disease's progression. The study employed ELISA to quantitatively measure IL-18 levels in 20 patient samples and 20 healthy control samples, providing insights into the correlation between IL-18 expression and AD severity. Results revealed a marked elevation of IL-18 in AD patients (59.38) compared to controls (14.38), underscoring the cytokine's potential role as a biomarker for AD progression and its involvement in the disease's inflammatory processes. These findings suggest that IL-18 could be a target for therapeutic intervention, offering new avenues for AD management and treatment.